Presentations
Monday November 16 - Ops Day
- Data Flow Through SCHARP or What Happened to My CRFs?
- Safety Reporting Essentials
- Review of Recent DAIDS Tox Table Clarification
- SCHARP Coding Queries
- Lab Program - Updates and Reminders
- New HIV Infection CRF
- Documentation of Training
- Randomization and Enrollment Calendar - Do's and Don'ts
- Atlas and Staff Delegation of Responsibilities Form
- SCHARP CRF Tracking System (CTS)
Tuesday November 17
Introduction to Vaccinology & Immunology
Studies in Response to the Step Study
- Introduction to Vaccinology & Immunology, Gail Broder
Studies in Response to the Step Study
- Ad Seroprevalence in the Step Study, Dan Barouch
- Analysis of the specificity of neutralizing antibodies to Ad5 and correlation with vaccine-induced immunity and infection in the STEP study: interim report, Cheng Cheng
- HIV-1 antigen-specific IgG isotype serology in infected volunteers from the STEP study, V520 protocol 023 (HVTN 502), John Moore
- Does Ad5 Gag-Pol-Nef Vaccination Elicit Antibodies that Enhance HIV Infection?, Donald Forthal
- Detection of Merck Ad5 Vaccine Vector and HIV-1 Insert Genes in HVTN 071: a Trial Using the MRKAd5 gag/pol/nef Vaccine from the Step Study, Tuofu Zhu
- Analysis of Ad5 Immune Complexes Generated from Ad5 Naturally Infected Vs. Ad5 Vaccinated Individuals. Ability of Ad5 IC To Activate a DC-T Cell Axis and Relationship with the Increased Acquisition of HIV Infection Within the STEP Trial, Giuseppe Pantaleo
- Sieve analysis of the Step trial: Evidence for vaccine-induced antigenic pressure on HIV, Allan deCamp and Peter Gilbert
- Granule Exocytosis-Mediated HIV-Specific Cytotoxicity Induced by the Merck Ad5 Trivalent Vaccine, Mark Connors
- HLA/KIR Analysis in STEP male vaccinees, Magda Sobieszczyk and Nicole Frahm
- Host genetics of T cell responses and Ad5 titers in the STEP trial, David Goldstein
Wednesday November 18
- Multivariate analyses in the Step Study or What's the story with HSV2, Ad5 and male circumcision??, Susan Buchbinder
- Phambili/HVTN 503 Interim Efficacy Analysis, Glenda Gray
The Thai Trial
- Primary Results of the Thai HIV Vaccine Trial, RV144, Supachai Rerks-Ngarm
- The End of the Beginning, Nelson Michael
- Lesson Learnt from Phase III Efficacy Trial in Thailand, Punnee Pitisuttithum
HVTN Science Tutorial
Thursday November 19
Early Career Investigators
- Strategies to Improve the Breadth and Focus of Vaccine-Elicited CD8+ T-Lymphocyte Responses, David Kaufman
- Role of Natural Killer Cells in Vaccine-Elicited Control of HIV/SIV Infections, R. Keith Reeves
- Dendritic Cell (DC)-targeting Lentivector as a New HIV Vaccine Platform, Lili Yang
- SIV/HIV-specific immune responses and virus evolution in breast milk, Sallie Permar
- Construction of a CD8 T cell epitope knockout live attenuated SIV vaccine for Mauritian cynomolgus macaques
, Shelby O'Connor